膀胱癌蛋白质基因组学特征揭示FGFR3突变肿瘤对肿瘤坏死因子相关凋亡诱导配体诱导的凋亡敏感
该研究对40例肌层浸润性膀胱癌和23例非肌层浸润性膀胱癌进行蛋白质基因组学分析,鉴定出5个蛋白质组分组,其中uPG-E与Ta通路及FGFR3突变相关。FGFR3突变肿瘤中凋亡相关蛋白富集,FGFR3激活调控TRAIL受体表达并使细胞对TRAIL介导的凋亡敏感,联合birinapant可进一步增强。
要点
- 蛋白质组分组uPG-E与Ta通路相关且富集FGFR3突变。
- FGFR3突变肿瘤中凋亡相关蛋白富集,转录组学未捕获。
- FGFR3激活调控TRAIL受体表达,联合birinapant增强凋亡。
核心结论
- 该蛋白质基因组学研究为研究非肌层浸润性和肌层浸润性膀胱癌异质性提供了全面资源,并提示TRAIL诱导的凋亡可能作为FGFR3突变膀胱肿瘤的治疗选择,值得开展临床研究。
研究设计与样本
- 研究纳入40例肌层浸润性膀胱癌和23例非肌层浸润性膀胱癌病例,获取蛋白质组数据,这些病例已有转录组和基因组数据。
- 对4株携带FGFR3改变的膀胱癌细胞系进行干预测试。
主要发现
- 无监督分析鉴定出5个蛋白质组分组,覆盖非肌层浸润性和肌层浸润性膀胱癌,与转录组亚型具有粗粒度相似性。
- uPG-E与Ta通路相关,并富集FGFR3突变。
- FGFR3突变肿瘤中凋亡相关蛋白富集,转录组学未捕获这一特征。
- 遗传和药理学抑制表明FGFR3激活调控TRAIL受体表达,并使细胞对TRAIL介导的凋亡敏感,与birinapant联合后进一步增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular understanding of muscle-invasive (MIBC) and non-muscle-invasive (NMIBC) bladder cancer is currently based primarily on transcriptomic and genomic analyses. OBJECTIVE: To conduct proteogenomic analyses to gain insights into bladder cancer (BC) heterogeneity and identify underlying processes specific to tumor subgroups and therapeutic outcomes. DESIGN, SETTING, AND PARTICIPANTS: Proteomic data were obtained for 40 MIBC and 23 NMIBC cases for which transcriptomic and genomic data were already available. Four BC-derived cell lines harboring FGFR3 alterations were tested with interventions. INTERVENTION: Recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), second mitochondrial-derived activator of caspases mimetic (birinapant), pan-FGFR inhibitor (erdafitinib), and FGFR3 knockdown. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Proteomic groups from unsupervised analyses (uPGs) were characterized using clinicopathological, proteomic, genomic, transcriptomic, and pathway enrichment analyses. Additional enrichment analyses were performed for FGFR3-mutated tumors. Treatment effects on cell viability for FGFR3-altered cell lines were evaluated. Synergistic treatment effects were evaluated using the zero interaction potency model. RESULTS AND LIMITATIONS: Five uPGs, covering both NMIBC and MIBC, were identified and bore coarse-grained similarity to transcriptomic subtypes underlying common features of these different entities; uPG-E was associated with the Ta pathway and enriched in FGFR3 mutations. Our analyses also highlighted enrichment of proteins involved in apoptosis in FGFR3-mutated tumors, not captured through transcriptomics. Genetic and pharmacological inhibition demonstrated that FGFR3 activation regulates TRAIL receptor expression and sensitizes cells to TRAIL-mediated apoptosis, further increased by combination with birinapant. CONCLUSIONS: This proteogenomic study provides a comprehensive resource for investigating NMIBC and MIBC heterogeneity and highlights the potential of TRAIL-induced apoptosis as a treatment option for FGFR3-mutated bladder tumors, warranting a clinical investigation. PATIENT SUMMARY: We integrated proteomics, genomics, and transcriptomics to refine molecular classification of bladder cancer, which, combined with clinical and pathological classification, should lead to more appropriate management of patients. Moreover, we identified new biological processes altered in FGFR3-mutated tumors and showed that inducing apoptosis represents a new potential therapeutic option.
引用
- Groeneveld CS, Sanchez-Quiles V, Dufour F, et al. Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors. Eur Urol. 2023. PMID: 37380559. doi:10.1016/j.eururo.2023.05.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。